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The use of high-dose chemotherapy with autologous support of hematopoietic progenitor
cells is an effective strategy to treat various hematologic neoplasms, such as non-Hodgkin
lymphomas and multiple myeloma. Mobilized peripheral blood progenitor cells are the
main source of support for autologous transplants, and collection of an adequate number
of  hematopoietic progenitor cells is a critical step in the autologous transplant procedure.
Traditional strategies, based on the use of growth factors with or without chemotherapy,
have limitations even when remobilizations are performed. Granulocyte colony-stimulating
factor is the most widely used agent for progenitor cell mobilization. The association of
plerixafor, a C-X-C Chemokine receptor type 4 (CXCR4) inhibitor, to granulocyte colony stim-
ulating factor generates rapid mobilization of hematopoietic progenitor cells. A literature
review was performed of randomized studies comparing different mobilization schemes
in  the treatment of multiple myeloma and lymphomas to analyze their limitations and
effectiveness in hematopoietic progenitor cell mobilization for autologous transplant. This
analysis showed that the addition of plerixafor to granulocyte colony stimulating factor is
well tolerated and results in a greater proportion of patients with non-Hodgkin lymphomas
or  multiple myeloma reaching optimal CD34+ cell collections with a smaller number of
apheresis compared the use of granulocyte colony stimulating factor alone.©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.High-dose chemotherapy with autologous hematopoietic
stem cell transplantation is an effective strategy to treat vari-
ous hematologic neoplasms, such as chemosensitive relapsed
Hodgkin’s lymphomas,1,2 non-Hodgkin lymphomas (NHL)3,4
5and multiple myeloma (MM). Several clinical guidelines
and consensus recommend the procedure as standard treat-
ment in these conditions.6–11 According to the Center for
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reserved.International Blood and Marrow Transplant Research
(CIBMTR), 12,047 autologous hematopoietic stem cell trans-
plantations (AHSCT) were carried out in the United States in
2011, with MM and NHL being the main indications.12 In Brazil,alvador, BA, Brazil.
data from the Brazilian Transplant Registry show that 1144
AHSCT were performed in 2013, slightly higher than the year
before.13
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
oter. 
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The CIBMTR shows that peripheral blood progenitor cells
re the main source used to support autologous transplants.12
n addition to the possible chemoresistance of the can-
er, mobilization of hematopoietic progenitor cells (HPC) is
nother potentially limiting step for AHSCT, with high failure
ates (between 5% and 40%) associated with historically used
obilization strategies.14
A consensus published by the American Society for Blood
nd Marrow Transplantation (ASBMT) recommends collecting
 minimum dose of 2 × 106 CD34+ cells/kg to perform AHSCT,
ut the decision to accept collections of between 1 × 106 and
 × 106 CD34+ cells/kg can be individualized according to the
ircumstances of each patient. On the other hand, larger target
umbers are needed if multiple transplants are planned.15
Although the minimum dose of progenitor cells to be
ollected is well deﬁned, the ideal target or the desirable max-
mum dose is less clear. Some data show that the use of
5 × 106 CD34+ cells/kg leads to quicker and more  predictable
rafting, achieving platelet transfusions independence sig-
iﬁcantly earlier with potential reductions in transplant
osts.16,17 Thus, adequate progenitor cell mobilization is a key
tep when planning an AHSCT.
iology  related  to  mobilization  of  hematopoietic
rogenitor  cells  and  therapeutic  targets
lthough mature hematopoietic cells are physiologically
eleased from the bone marrow to the peripheral blood, imma-
ure cells are found in the circulation at a very low frequency.
bout 0.05% or less of the total circulating leukocytes are
PC and express the CD34+ surface marker.18 HPC adhere
o the bone marrow microenvironment by a variety of adhe-
ive interactions.19 Furthermore, they express a wide range
f surface receptors, such as adhesion molecules associated
ith angiopoietin-1 lymphocytes, very late antigen 4 (VLA4),
nd Mac-1, C-X-C chemokine receptors type 4 (CXCR4) and
ype 2 (CXCR2), the surface glycoproteins CD44 and CD62L,
nd tyrosine kinase receptor c-kit.19 The bone marrow stroma
ontains stromal cell-derived factor 1 (SDF-1), CXC chemokine
RO-, vascular cell adhesion molecule (VCAM-1), KIT-ligand,
-selectin glycoprotein ligand and hyaluronic acid, all of
hich are ligands for the stem cell adhesion molecules.20
reclinical data show that inhibition of these receptor–ligand
nteractions results in increased mobilization of progenitor
ells.19–21
Growth factors [granulocyte colony-stimulating factor
G-CSF), granulocyte-macrophage colony-stimulating factor
GM-CSF)] are the most widely used agents for progeni-
or cell mobilization; they have two main mechanisms of
ction. The ﬁrst is the production of proteases by hyper-
lastic myelomonocytic series, which induces the cleavage
f SDF-1 by preventing its binding to CXCR4. The most stud-
ed protease is matrix metallopeptidase 9 (MMP-9), although
ipeptidase CD26 seems to have a greater role in this
rocess.22,23 The second main mechanism is also proteoly-
is induced and is responsible for degradation of VCAM-1,
steopontin and ﬁbronectin, leading to reduced adhesion of
rogenitor cells through its VLA-4 receptor in bone marrow
troma.232 0 1 6;3 8(1):28–36 29
The addition of a chemotherapeutic agent to a cytokine
in the mobilization regimen has effects which are not fully
elucidated.19 It is speculated that the addition of cyclophos-
phamide to growth factors has a synergistic effect on the
release of granulocytic proteases in the bone marrow as its
administration in isolation leads to cleavage of SDF-1, CXCR4
and c-kit adhesion molecules.19 Furthermore, the toxicity of
chemotherapeutic agents on bone marrow stroma can release
HPC as a result of damage to the functional ability of stromal
cells in supporting them.19
Plerixafor (AMD3100) is a reversibly bicyclam inhibitor of
CXCR4 that breaks the binding between SDF-1 and CXCR4
receptors, blocking the chemotactic signaling with stromal
cells.23 Among the hypotheses for its mobilization mechanism
is the loss of sensitivity of progenitor cells to SDF-1 caused
by the inhibition of CXCR4. Consequently, these cells are
attracted to the circulation through signaling probably related
to sphingosine-1-phosphate (S1P), a sphingolipid implicated
in the chemotaxis control of progenitor cells from bone mar-
row, blood and other tissues.23 Studies also suggest that
plerixafor keeps the progenitor cells in the circulation by
binding to CXCR4, leading to a loss of chemoattraction to
SDF-1, decreasing HPC homing, which also contributes to
mobilization.24
Mobilization  of  hematopoietic  progenitor  cells
for multiple  myeloma  and  lymphoma:  results  of
the  historically  most  used  strategies  show
limitations
Traditionally, the most widely used mobilization strategies
have been the use of growth factors alone (G-CSF/GM-CSF)
or in combination with chemotherapeutic agents. Among
the available growth factors, the most commonly used is
recombinant G-CSF ﬁlgrastim, while others, such as, G-CSF
pegﬁlgrastim, G-CSF lenograstim and GM-CSF molgramostim,
are used less frequently.14
G-CSF alone as ﬁrst-line mobilization is an attractive option
owing to the predictable mobilization kinetics, which in turn
allows predictable apheresis scheduling and stafﬁng while
decreasing costs of growth factors and the collection proce-
dure compared with cyclophosphamide (CY).25–27
GM-CSF has been shown to be inferior to G-CSF in terms
of number of stem cells collected and in post-transplantation
outcomes related to hematopoietic recovery, transfusion and
antibiotic support, febrile episodes and hospitalizations.28,29
It is most often used in remobilization strategies, alone or
in combination with other cytokines or chemotherapy.28,29
Data on the use of pegﬁlgrastim in steady-state mobiliza-
tion are both limited and mixed, but one study demonstrated
predictable mobilization kinetics and similar collection
yields and apheresis days compared with a separate G-CSF
cohort.30
CY may be incorporated into the initial induction or sal-
vage therapy cycles, or may be administered as a standalone
cycle separately from standard therapy. The most common
stand-alone regimens include cyclophosphamide at a range of
doses between 2 and 7 g/m2. CY is associated with higher cell
yields, lower or similar failure rates,25–27,31–34 and improved
mote
was achieved by 90% with the combination against 59.8% in
the G-CSF group within four apheresis days (p-value < 0.001)30  rev bras hematol he
engraftment kinetics,35–40 but also may result in more  tox-
icity, febrile neutropenia, transfusions, hospitalizations and
higher costs.14,34,41 The published literature on the various CY
approaches is vast. In general, studies demonstrate that CY
will mobilize more  stem cells than G-CSF alone and help in
the role of mobilizing traditionally difﬁcult patients, such as
those with lymphoma.42,43
The primary goal of mobilization is to collect a sufﬁcient
number of progenitor cells for the patient to undergo AHSCT.
The optimal mobilization, however, requires collection of a
target number of cells and also strategies to minimize the time
and number of apheresis, reducing the cost of the procedure
and avoiding complications related to mobilization, such as
hospitalization due to febrile neutropenia.15
A systematic review of randomized clinical trials evalu-
ated the results of 28 studies comparing different mobilization
schemes. Eighteen included only patients with MM and/or
lymphomas14 and only four of these were multicenter.
Table 1 shows the characteristics of interventions and results
observed in studies included in this systematic review that
recruited ≥10 patients in each arm and compared different
regimens of growth factors with and without chemotherapy
(Table 1).
These studies show that, in general, strategies with higher
doses of G-CSF alone or chemotherapy with the addition of
growth factors (G-CSF and/or GM-CSF) result in increased
number of CD34+ cells collected. Furthermore, some strate-
gies reduced the number of apheresis needed to achieve target
collection.14
Although this systematic review has limitations such as
restricted sample size of studies, their moderate quality and
variability in the population, it demonstrates the limitations
of techniques historically used in HPC mobilization. A major
retrospective analysis, involving 2177 patients undergoing
attempted mobilization in three Italian centers between 1999
and 2007, showed a rate of poor mobilizers (deﬁned as a collec-
tion of <2 × 106 CD34+ cells/kg) of only 15% corroborating data
from randomized trials.44
Insufﬁcient initial mobilization leads to new mobilization
procedures (remobilization), which can negatively inﬂuence
disease progression and signiﬁcantly increase the use of
resources.41 Several studies evaluated the success of remobi-
lization with traditional measures based on the use of growth
factors. A retrospective analysis assessed the results of remo-
bilization of regimens containing G-CSF and/or GM-CSF, alone
or combined with chemotherapy in 251 patients with lym-
phoma or MM.41 After remobilization, only 18.4% of patients
who  used G-CSF or GM-CSF and 26.5% of those who received a
growth factor associated with chemotherapy achieved collec-
tions of ≥2 × 106 CD34+ cells/kg. When cells collected in the
ﬁrst mobilization were pooled, the failure rates were 28.1%
in the group remobilized with growth factor alone and 47.1%
in the group remobilized with growth factor associated with
chemotherapy (Table 2).41
Published data suggest that, although remobilization with
growth factors can rescue patients who  failed the ﬁrst mobi-
lization, the proportion of patients not meeting the minimum
collection of HPC required to perform AHSCT is high (around
30%), conﬁrming the need to evaluate more  effective mobiliza-
tion strategies.r. 2 0 1 6;3 8(1):28–36
Challenges  for  the  identiﬁcation  and
prospective  characterization  of  poor  mobilizers
after  strategies  based  on  the  use  of  growth
factors
The possibility of predicting mobilization failure based on
patient’s characteristics in the early mobilization process is
highly debatable.15 Each study proposes different deﬁnitions
of poor mobilizers, limiting the uniformity of the characteris-
tics that prospectively identify these patients.18
Some identiﬁable characteristics before mobilization have
often been associated with a higher risk of failure of
procedures in patients with lymphoproliferative diseases.29
Although some of these factors are unanimously pointed out
in the literature as predictive of poor mobilization, such as
the intensity of prior exposure to chemotherapy or radiation,
the use of chemotherapeutic agents and failure in a previous
attempt of mobilization others, such as patient age, have a
more  controversial relationship with poor mobilization.47
The Italian working group, Gruppo Italiano Trapianto di
Midollo Osseo (GITMO), recently proposed a deﬁnition for ‘poor
mobilizers’ for patients with lymphoma or myeloma.48 This
deﬁnition came from a consensus of experts and considers
the factors described in Table 3.
The concept of proved poor mobilizer based on the cir-
culating CD34+ cell count after 4–6 days of mobilization is
very relevant given the availability of preemptive strategies
with potential for reducing risk of complications related to the
necessity of a greater number of apheresis or higher need for
remobilizations and possible reduced cost.
Use  of  plerixafor  to  mobilize  hematopoietic
progenitor  cells:  randomized  clinical  trials
showing  its  effectiveness
Plerixafor has proved to be an agent that generates rapid mobi-
lization of HPC in murine models and subsequently in healthy
human volunteers.49 The phase I and II studies attested the
mobilizing effect and safety of the G-CSF plus plerixafor
combination in patients with NHL and MM.  The rapid and
signiﬁcant increase in white blood and CD34+ cell counts in
peripheral blood, included patients whose failure to mobilize
with G-CSF alone was proven.49–51 The combination guaran-
teed collections of ≥2 × 106 CD34+ cells/kg in 95.9% of patients
with 77.6% achieving a collection of ≥5 × 106 CD34+ cells/kg
(22.4% of patients achieved this dose after only one apheresis).
Two randomized, comparative, double-blind, placebo con-
trolled and prospective multicenter studies evaluated the
use of G-CSF plus plerixafor versus G-CSF alone in the ini-
tial mobilization strategy of patients. These studies recruited
298 patients with NHL52 and 302 patients with MM.53 NHL
patients treated with the combined therapy obtained 65.6%
of successful collections of ≥5 × 106 CD34+ cells/kg versus
24.2% in the G-CSF arm. Collection of ≥2 × 106 CD34+ cells/kg(Figure 1). The median number of CD34+ cells collected was
also higher in combination group (5.69 × 106 cells/kg versus
rev bras hematol hemoter. 2 0 1 6;3 8(1):28–36 31
Table 1 – Randomized clinical trials evaluating different mobilization strategies including growth factors with/without
chemotherapy.14
Study Interventions (n) Collected
CD34+ cells
(median/×106)
Number of
apheresis
(median)
Patients
failed to
mobilize (%)
Cyclophosphamide associated with growth factor
Facon et al., 1999 CY  4 g/m2 + ﬁlgrastim 5 mcg/kg/d + ancestim
20 mcg/kg/d (n = 55)
12.4a 1a 14.5
CY 4 g/m2 + ﬁlgrastim 5 mcg/kg/d (n = 47) 8.2 2 19.1
Gazitt et al. 2000 CY 3 g/m2 + molgramostim 250 mcg/m2 (n = 10) NR 2 40.0
CY 3 g/m2 + ﬁlgrastim 10 mcg/kg/d (n = 13) NR 3 23.0
CY 3 g/m2 + molgramostim 250 mcg/m2 + ﬁlgrastim
10 mcg/kg/d (n = 12)
NR  1 41.7
Narayanasami et al. 2001 Filgrastim 10 mcg/kg/d (n = 23) 2.5 No difference NR
CY 5 g/m2 + ﬁlgrastim 10 mcg/kg/d (n = 24) 7.2* No difference NR
Pavone et al. 2002 DHAP + ﬁlgrastim 5 mcg/kg/d (n = 38) 5.9 2 13.2
CY + ﬁlgrastim 5 mcg/kg/d (n = 34) 7.1 2 11.8
Vela-Ojeda et al. 2000 IFO + molgramostim 5 mcg/kg/d (n = 28) 3.1 3 14.3
CY 4 g/m2 + molgramostim 5 mcg/kg/d (n = 28) 5.3 3 10.7
Growth factor alone
Stiff et al. 2000 Filgrastim 10 mcg/kg/d (n = 51) 3.6 NR 26.0
Filgrastim 10 mcg/kg/d + ancestim 20 mcg/kg/d (n = 56) 2.4 NR 16.4
Other chemotherapy combinations associated with growth factors
Copelan et al. 2009 R  + VP-16 + ﬁlgrastim 10 mcg/kg/d (n = 28) 9.9* 3 3.6
VP-16 + ﬁlgrastim 10 mcg/kg/d (n = 27) 5.6 4 14.8
Hart et al. 2009 IEE + ﬁlgrastim 5 mcg/kg b.i.d + EPO (n = 14) 15.4 1.3 0
IEE + ﬁlgrastim 5 mcg/kg b.i.d (n = 12) 12.6 1.8 16.7
Ozcelik et al. 2009 CE  + ﬁlgrastim 10 mcg/kg/d (late) (n = 23) 10.8 1 13.0
CE + ﬁlgrastim 10 mcg/kg/d (early) (n = 25) 10.5 1 16.0
CY: cyclophosphamide; IFO: ifosfamide; DHAP: dexamethasone + cytarabine + cisplatin; IEE: ifosfamide + epirubicin + etoposide; EPO: erythro-
1
t
s
g
n
e
ppoietin; CE: cyclophosphamide + etoposide; NR: not reported.
a Statistically signiﬁcant difference.
.98 × 106 cells/kg).52 Incidence of adverse events, mostly mild
o moderate, was similar between groups with only 5.3% of
erious events in the combination group and 6.9% in the G-CSF
52roup during the mobilization period. The most common
on-serious adverse events were diarrhea (38%), injection site
rythema (29.3%), nausea (17.3%), headache (11.3%) and bone
ain (10.7%), all of which were easily manageable.52
Table 2 – Results obtained with remobilization with G-CSF and/
Study and disease Remobilization
regimen (n)
Mobilized CD
(median/fail
Pusic et al., 200841
– lymphomas (n = NR)
– multiple myeloma (n = NR)
G-CSF/GM-CSF
(n  = 217)
1.2 × 106/81.6%
G/C (n = 34) 0.9 × 106/73.5%
Lefrere et al. 200445:
– lymphomas (n = 64)
– myeloma (n = 28)
– acute leukemia (n = 27)
– solid tumors (n = 19)
G-CSF + chemotherapy
(cyclophosphamide in
57%)
(n = 138)
3.5 × 106/35% 
Boeve et al. 200446:
– lymphoma
– myeloma
Other cancers
G-CSF in high doses or
G-CSF + GM-CSF
(n = 86)
2.1 × 106/65% f
lymphoma
3.5% for myelo
31.5% for othe
G/C: growth factor associated with chemotherapy; NR: not reported.MM patients treated with G-CSF plus plerixafor obtained
≥6 × 106 CD34+ cells/kg within two  apheresis days, with 86.8%
achieving this target versus 55.9% in the G-CSF group (p-value
<0.0001). The combination was also more  effective to collect
≥6 × 106 CD34+ cells/kg within four apheresis days (75.7% vs.
51.3%; p-value <0.001) and ≥2 × 106 CD34+ cells/kg days (95.3%
vs. 88.3%; p-value = 0.031)36 (Figure 2). The median number of
or GM-CSF with or without chemotherapy.
34+ cells
ure rate)
Apheresis
days (median)
Apheresis days
considering all
mobilizations
(median)
Failure rate
considering all
mobilizations after
cells pooled (%)
 3 6 28.1
 2 6 47.1
2 NR 22.5
or
ma
r cancers
3  NR 26.7 after 2
mobilizations
and 15 after 3
mobilizations
32  rev bras hematol hemoter. 2 0 1 6;3 8(1):28–36
Table 3 – Deﬁnitions for patients with lymphoma or myeloma who have prediction or evidence of poor mobilization.
Predicted poor mobilizer At least one major criterion or two minor criteria:
• Major criteria:
© Failure of previous attempt to mobilize;
© Prior radiotherapy involving large areas containing bone marrow;
© Complete courses of prior therapy including melphalan, ﬂudarabine or other therapies that potentially affect
progenitor cell mobilization such as carmustine, dacarbazine, cladribine, lenalidomide, and platinum
compounds.
• Minor criteria:
© At least two previous lines of cytotoxic therapy;
© Refractory disease;
© Lymphoma is a higher risk factor than myeloma
© Extensive involvement of bone marrow inﬁltration by tumor cells;
© Bone marrow cellularity <30% in mobilization;
© Low platelet count before deployment.
© Age >65 years.
Proved poor mobilizer • Having received adequate mobilization (G-CSF doses ≥10 mcg/kg if used alone or ≥5 mcg/kg if used after
chemotherapy) and present:
© a peak of circulating CD34+ cells <20/L  on days 4–6 after the start of mobilization with G-CSF alone or within
20 days after chemotherapy with G-CSF
OR
• Collection of CD34+ cells <2 × 106/kg in up to three apheresis
o OssAdapted by Jantunen et al.47 and Gruppo Italiano Trapianto di Midoll
CD34+ cells collected was also higher in the combination group
(12.97 vs. 7.31 × 106 cells/kg). The incidence of adverse events
was similar between study groups. The most common non-
serious adverse events occurred were injection site erythema
(20.4%), diarrhea (18.4%), nausea (16.3%), bone pain (9.5%) and
fatigue (8.2%), all of which were easily manageable.53 The
majority of these events occurred in the period after mobi-
lization and were unrelated to the study drug.53
These studies show that the combination of plerixafor with
G-CSF is well tolerated and results in a greater proportion
of NHL or MM patients achieving CD34+ cell collections con-
sidered optimal for transplant within a smaller number of
apheresis days when compared with G-CSF alone.
Strategies  for  preemptive  use  of  plerixafor
Many  studies, including phase III studies, have shown that
the use of plerixafor reduces risk of poor progenitor cell mobi-
lization and risk of failure from up to 40% to less than 10%.
However, the cost of plerixafor may be a limiting factor for its
unrestricted use in the initial mobilization.54
An alternative strategy discusses the use of plerixafor
as rescue treatment in patients failing prior mobilization.
Micallef et al. analyzed 52 patients with NHL who failed the ini-
tial mobilization with G-CSF in a phase III study. The analysis
showed that patients who  received remobilization with G-CSF
associated with plerixafor presented a median collection of
2.9 × 106 CD34+ cells/kg in remobilization after a median of
three apheresis.55 In this study, 63.5% of patients achieved
a collection of ≥2 × 106 CD34+ cells/kg in up to four aphere-
sis days in the second mobilization and 88.75% were able to
undergo the transplant.
Some centers developed algorithms for the preemptive use
of plerixafor in which patients initially receive customary regi-
mens for mobilization. In this case, plerixafor is indicated, ifeo.48
necessary, to immediately rescue patients with veriﬁed poor
mobilization before collection of progenitor cells.17,56
One study evaluated 314 patients with myeloma, amyloid-
osis or lymphoma undergoing mobilization with G-CSF and
tested two algorithms for plerixafor use. One used plerixafor
only in patients with a CD34+ cell count in peripheral blood
of <10/L on Day 4 of mobilization or on any day of aphere-
sis, with collections of <0.5 × 106 CD34+ cells/kg (plerixafor-1
algorithm – including 216 patients). The other used plerix-
afor if CD34+ cell count in peripheral blood reached <10/L
on Day 4 of mobilization (<20/L if multiple transplants were
planned) or if collection was <1.5 × 106 CD34+ cells/kg on
Day 1 of apheresis or <0.5 × 106 CD34+ cells/kg in any sub-
sequent apheresis day (plerixafor-2 algorithm – including 98
patients). The target was the collection of ≥4 × 106 CD34+
cells/kg (optimal collection) or ≥2 × 106 CD34+ cells/kg (min-
imum collection). The results were compared with those
obtained in another cohort of 278 patients mobilized before
the introduction of plerixafor, and with data from the same
prospective database of transplant (Mayo Clinic), presenting
similar characteristics.57 Some other studies evaluating dif-
ferent algorithms for the preemptive use of plerixafor showed
lower collecting failure rates of 0–7%.57,58
A review of pharmacoeconomic studies presented some
algorithms for the preemptive use of plerixafor that resulted
in reduced consumption of several health resources, includ-
ing the possibility of reducing the total cost of mobilization
procedures.54
Cost  effective  analysesThere are some analyses related to plerixafor cost–beneﬁt in
front line and in remobilization scenarios,56,59–62 but they were
not performed in Brazilian institutions nor did they analyze
real private or public costs. Another important question about
rev bras hematol hemoter. 2 0 1 6;3 8(1):28–36 33
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Figure 1 – Percentage of patients with non-Hodgkin
lymphoma achieving collection targets of ≥5 × 106 CD34+
cells/kg (A) and of ≥2 × 106 CD34+ cells/kg (B) after
mobilization with G-CSF plus placebo or G-CSF plus
plerixafor.
Adapted from DiPersio et al.52
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Figure 2 – Percentage of patients with multiple myeloma
achieving collection targets of ≥6 × 106 CD34+ cells/kg after
mobilization with G-CSF plus placebo or G-CSF plus
plerixafor.
Adapted from DiPersio et al.53
Table 4 – Cost analysis.
Baseline Plerixafor-1 Plerixafor-2 p value
Patients 280 219 98
Total cost per patienta
Median $12,500 $12,500 $20,000
Minimum $3000 $5000 $5500
Maximum $146,750 $93,000 $89,750 0.01
Mean $17,150 $21,532 $20,617
Adapted from Micaleff et al.56
a Cost analysis includes remobilization costs and has been added
to the original mobilization regardless of when the remobilization
occurred.
these analyses is that the calculated costs did not include
supportive care costs, including transfusions, antimicrobials,
hospitalization, cryopreservation, nursing and medical costs,
patient’s personal costs, logistics, or even costs with previous
failures, remobilization56,59–62 and, speciﬁcally, the worse out-
come in lymphoma and myeloma patients failure to undergo
AHSCT.41,63,64,65
In the study of Micallef et al.,56 although the earlier identi-
ﬁcation of poor mobilizers and addition of plerixafor results
in higher per-patient costs over baseline, it is associated
with higher apheresis yields, fewer days of mobilization and
collection, and lower failure rates. The median total costs
of mobilization per patient, including any remobilization
attempt, was US$12,500 in the baseline group, US$12,500 in
the plerixafor-1 group, and US$20,000 in the plerixafor-2 group
(Table 4). Although both the median and mean costs were
higher in the plerixafor-2 group, the mobilization failure rate
was 1%, with fewer days of apheresis, fewer days of plerixafor,
and fewer total days of mobilization and collection compared
to the plerixafor-1 algorithm.56 There is an urgency to have
more accurate pharmacoeconomic matrixes to calculate the
other important and neglected costs mentioned above and to
decide about the real cost–beneﬁt in each institution.
Consensus recommendations suggest the use of plerix-
afor as a mobilization strategy particularly in patients with a
higher target for collection of progenitor cells, as a preemptive
approach based on the monitoring of the CD34+ cell count and
in cases of remobilization.15 The European Group for Blood
Apheresis (target cell count = 2.0 Mio CD34+ cells/kg BW)+
Pre-emptive plerixafor
<10 cells/μL
CD34+ cell count prior to apheresis
10-20 cells/μL>20 cells/ μL∗
Dynamic approach
based on the
patient’s disease
characteristics and
treatment history
Figure 3 – European Group for Blood and Marrow
Transplantation position regarding mobilization.
Adapted from Mohty et al.31
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and Marrow Transplantation (EGBMT) recommends preemp-
tive use of plerixafor in patients with CD34+ cell counts <10/L
before apheresis31 (Figure 3). Each center should develop and
implement its own algorithms for applying different mobiliza-
tion strategies, with the goal of optimizing collection yields
and costs–beneﬁts.
Conclusion
Collection of adequate numbers of HPC is a critical step in
autologous transplantation procedures. Traditional strategies,
based on the use of growth factors with or without chemother-
apy, have some limitations even when remobilizations are
performed.
The addition of plerixafor shows a consistent increase in
collection rate success, reducing the number of apheresis and
not increasing toxicity. Strategies of preemptive use of plerix-
afor have been considered a promising way to optimize and
rationalize the use of this agent in patients who have high
chance of failure with classic mobilization based on G-CSF
with or without chemotherapy. This strategy would reduce
failure in mobilization, especially in poor mobilizers, ensuring
collection and transplantation as well as reducing time and
costs of the mobilization procedure. However, external valid-
ity of these algorithms is limited, so it is recommended that
each institution sets up a strategy appropriate to its standards
for the preemptive use of plerixafor.
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